- Home
- NOV vs TLX Comparison
NOV vs TLX Comparison
Compare NOV & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOV
- TLX
- Stock Information
- Founded
- NOV 1862
- TLX 2015
- Country
- NOV United States
- TLX Australia
- Employees
- NOV N/A
- TLX N/A
- Industry
- NOV Metal Fabrications
- TLX Biotechnology: Pharmaceutical Preparations
- Sector
- NOV Industrials
- TLX Health Care
- Exchange
- NOV Nasdaq
- TLX Nasdaq
- Market Cap
- NOV 5.6B
- TLX 6.0B
- IPO Year
- NOV 1996
- TLX N/A
- Fundamental
- Price
- NOV $14.26
- TLX $16.75
- Analyst Decision
- NOV Buy
- TLX Strong Buy
- Analyst Count
- NOV 16
- TLX 1
- Target Price
- NOV $19.60
- TLX $22.00
- AVG Volume (30 Days)
- NOV 4.3M
- TLX 56.0K
- Earning Date
- NOV 04-24-2025
- TLX 01-01-0001
- Dividend Yield
- NOV 2.10%
- TLX N/A
- EPS Growth
- NOV N/A
- TLX 798.14
- EPS
- NOV 1.60
- TLX 0.09
- Revenue
- NOV $8,870,000,000.00
- TLX $484,687,790.00
- Revenue This Year
- NOV $0.35
- TLX N/A
- Revenue Next Year
- NOV $3.17
- TLX N/A
- P/E Ratio
- NOV $8.91
- TLX $178.45
- Revenue Growth
- NOV 3.34
- TLX 55.85
- 52 Week Low
- NOV $13.78
- TLX $14.01
- 52 Week High
- NOV $21.20
- TLX $30.36
- Technical
- Relative Strength Index (RSI)
- NOV 40.75
- TLX N/A
- Support Level
- NOV $13.78
- TLX N/A
- Resistance Level
- NOV $15.41
- TLX N/A
- Average True Range (ATR)
- NOV 0.49
- TLX 0.00
- MACD
- NOV -0.07
- TLX 0.00
- Stochastic Oscillator
- NOV 26.97
- TLX 0.00
About NOV NOV Inc.
NOV (formerly National Oilwell Varco) is a leading supplier of oil and gas drilling rig equipment and products, such as downhole tools, drill pipe, and well casing. The company operates on a global scale, with international markets contributing nearly two thirds of its annual revenue.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.